Wednesday, May 14, 2014

PERNIX signs agreement to acquire TREXIMET Tablets for Migraine from GlaxoSmithKline

Pernix Therapeutics Holdings, today announced that it has signed an agreement with GlaxoSmithKline to acquire the U.S rights to Treximet for the acute treatment of migraine attacks with or without aura in adults. The acquistion adds immediate revenues and earnings for Pernix.  The net sales for Treximex for the full year of 2013 was 78.7 million.  This deal is expected to double Pernix's revenue for 2014.  Pernix will make an upfront payment to GSK of $250 million for the U.S rights to Treximet.  Here is the full story on Pernix's website.